Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Other Current Receivables: ¥254 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603707 Nanjing King-Friend Biochemical Pharmaceutical Co Ltd SHSE:603707
71 GF Score
Price ¥8.08
GF Value ¥12.71
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Nanjing King-Friend Biochemical Pharmaceutical Co Other Current Receivables?

Nanjing King-Friend Biochemical Pharmaceutical Co SHSE:603707 -1.58% 71 Other Current Receivables is ¥254 Mil as of Mar. 2026. GuruFocus rates SHSE:603707 with a GF Score™ of 71/100 and a GF Value™ of ¥12.71 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Nanjing King-Friend Biochemical Pharmaceutical Co's Other Current Receivables for the quarter that ended in Mar. 2026 was ¥254 Mil.

Nanjing King-Friend Biochemical Pharmaceutical Co's quarterly Other Current Receivables declined from Sep. 2025 (¥271.78 Mil) to Dec. 2025 (¥248.45 Mil) but then increased from Dec. 2025 (¥248.45 Mil) to Mar. 2026 (¥254.06 Mil).

Nanjing King-Friend Biochemical Pharmaceutical Co's annual Other Current Receivables increased from Dec. 2023 (¥251.27 Mil) to Dec. 2024 (¥284.21 Mil) but then declined from Dec. 2024 (¥284.21 Mil) to Dec. 2025 (¥248.45 Mil).

Nanjing King-Friend Biochemical Pharmaceutical Co Other Current Receivables Related Terms

Nanjing King-Friend Biochemical Pharmaceutical Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing King-Friend Biochemical Pharmaceutical Co Other Current Receivables Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 228.33 263.95 251.27 284.21 248.45

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 294.89 261.35 271.78 248.45 254.06
SHSE:603707
71GF Score
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd SHSE:603707
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing King-Friend Biochemical Pharmaceutical Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ¥254 Mil mean?
Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) has a Other Current Receivables of ¥254 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Nanjing King-Friend Biochemical Pharmaceutical Co and its competitors.
Is Nanjing King-Friend Biochemical Pharmaceutical Co's Other Current Receivables too high?
Nanjing King-Friend Biochemical Pharmaceutical Co's current Other Current Receivables is ¥254 Mil. Overall, Nanjing King-Friend Biochemical Pharmaceutical Co has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing King-Friend Biochemical Pharmaceutical Co's Other Current Receivables compare to ZTS?
Nanjing King-Friend Biochemical Pharmaceutical Co's Other Current Receivables of ¥254 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Nanjing King-Friend Biochemical Pharmaceutical Co and its competitors. Nanjing King-Friend Biochemical Pharmaceutical Co's current Other Current Receivables is ¥254 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing King-Friend Biochemical Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥12.71, compared to a current price of ¥8.08 — trading 36.4% below its estimated fair value. The current Other Current Receivables is ¥254 Mil. Nanjing King-Friend Biochemical Pharmaceutical Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707), the current Other Current Receivables is ¥254 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing King-Friend Biochemical Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥8.08 is trading 36.4% below its estimated GF Value™ of ¥12.71. GuruFocus considers Nanjing King-Friend Biochemical Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:603707:

  • Other Current Receivables: ¥254 Mil
  • GF Value™: ¥12.71 vs. price of ¥8.08 (36.4% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanjing King-Friend Biochemical Pharmaceutical Co Business Description

Address 1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
71GF Score

Get the complete analysis for SHSE:603707

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.08
Price
¥12.71
GF Value